Brandon C. Heitmeier
Investigator / Regulatory Officer, U.S. Public Health Service
ORA New Orleans District (Nashville, TN)
Aseptic processing and sterile compounding specialist whose inspections have directly led to warning letters and a consent decree — known for documenting granular facility defects and testing validation study representativeness.
Inspection Approach
How Brandon Inspects
Heitmeier brings a methodical, detail-oriented approach to sterile manufacturing inspections, with every publicly available 483 containing multiple observations about aseptic processing, cleanroom conditions, and personnel practices. He begins with a thorough facility walkthrough, documenting granular physical defects — chips, scratches, stains on cleanroom walls, worn equipment surfaces, and gap measurements — that other investigators might overlook.
A signature pattern is his scrutiny of the representativeness of validation studies. At The Wellness Center Pharmacy, he identified that media fill batch sizes (25 vials) bore no resemblance to actual production volumes (10L ophthalmic product), rendering the validation scientifically meaningless. He similarly examines whether environmental monitoring is continuous or merely periodic, citing facilities that checked pressure differentials only once daily.
Heitmeier's inspections carry significant enforcement weight. His findings at Delta Pharma directly led to a consent decree of permanent injunction barring operations, and his re-inspection of The Wellness Center Pharmacy two years after the initial 483 demonstrates follow-through on compliance commitments. When he returns to a facility, he expects every prior observation to be fully remediated.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
The Wellness Center Pharmacy, Inc. (dba Designer Drugs)
- Personnel gowning inadequate — polypropylene isolation gowns, earloop masks, and bouffant caps were non-sterile and failed to cover operator skin on face, neck, and clothing
- ISO 5 laminar airflow hood lacked air pressure gauge for monitoring pressure differentials; differentials only checked once daily, not continuously
- Environmental monitoring (surface, air, personnel) performed only every two weeks, not each production day
- Potency testing of drug products performed at discretion of pharmacist-in-charge, not per established protocol
Delta Pharma, Inc.
- Kick plates in ISO 7 and ISO 8 areas not cleaned during pre-production cleaning procedures
- Approximately 7 chips and scratches on cleanroom walls; 3 brown stains on cleanroom floor
- Sterilisation process validation not established for injectable sterile products
- Dexamethasone Acetate Suspension lot failed potency/purity specifications — firm discarded lot but QU failed to investigate the failure
- Led to consent decree of permanent injunction barring operations until FDA authorisation
The Wellness Center Pharmacy, Inc. (dba Designer Drugs)
- Laminar airflow hood plastic cover dislodged, exposing inner housing not included in cleaning procedures
- Media fill batch size (25 vials) not representative of actual production volume (10L ophthalmic product)
- Cleanroom equipment showing age-related wear — re-inspection found persistent deficiencies from 2015
Pre-Inspection Preparation
How to Prepare
- 1 Audit aseptic gowning thoroughly — Heitmeier documents exposed skin, non-sterile garments, and inadequate coverage with precision. Ensure all garments are sterile and provide full coverage.
- 2 Verify continuous environmental monitoring — he has cited facilities for checking pressure differentials only once daily. Install alarmed continuous monitoring systems.
- 3 Ensure environmental monitoring covers every production day — surface, air, and personnel monitoring must occur each day sterile products are manufactured.
- 4 Walk cleanroom walls, floors, and ceilings before any inspection — Heitmeier documents chips, scratches, stains, and worn surfaces at a granular level.
- 5 Validate that media fill batch sizes are representative of actual production volumes — a 25-vial media fill for a 10L production batch will be cited.
- 6 Ensure sterilisation processes are fully validated with current documentation — absence of validation has led to consent decrees from his inspections.
- 7 Audit pre-production cleaning procedures to confirm all surfaces are included — he cited kick plates in ISO 7/8 areas being skipped during cleaning.
- 8 Verify all production equipment calibration records are current with visible indicators — he checks calibration stickers during facility walkthroughs.
- 9 Ensure the quality unit investigates all OOS results thoroughly — at Delta Pharma, failure to investigate a potency/purity OOS contributed to a permanent injunction.
- 10 Prepare for re-inspection by verifying all prior 483 observations are fully remediated — Heitmeier returns to facilities and expects complete resolution.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Brandon C. Heitmeier — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
